Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

Stem cells—a hard sell to investors

Nature Biotechnology volume 23, pages 798–800 (2005)Cite this article

A lack of proven commercial success and a surfeit of ethical, legal and political problems make stem cell companies a difficult pitch to venture capitalists.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Market performance of 5 'stem cell' companies illustrates the volatility of the group compared with the Nasdaq general biotech stock index.

Author information

Authors and Affiliations

  1. SV Life Sciences,

    Lutz B Giebel

  2. Cythera Inc.,

    Lutz B Giebel

  3. Novocell Inc.,

    Lutz B Giebel

Authors
  1. Lutz B Giebel
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Giebel, L. Stem cells—a hard sell to investors. Nat Biotechnol 23, 798–800 (2005). https://doi.org/10.1038/nbt0705-798

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0705-798

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing